Objective: To determine if patient self-administration of hydrocortisone will safely achieve superior symptom control for all hydrocortisone-responding disorders as it does for Addison’s disease and rheumatoid arthritis.
Methods: Two thousand four hundred and twenty-eight participants with hydrocortisone-responding disorders were brought to a minimum symptom state using daily administered hydrocortisone tablets in a 24-week, open study. Thereafter, participants used 5-day, low-dose hydrocortisone regimens to quench subsequent disorder exacerbations (flares) to maintain the minimum symptom state. Stressors such as emotional traumas, infections, allergies, and injuries were minimized to reduce disorder intensity, hydrocortisone consumption, and participant discomfort.
Results: Two thousand fifteen participants, 601 with fibromyalgia, 579 with osteoarthritis, 246 with rheumatoid arthritis, 226 with undifferentiated arthritis, 75 with back pain, 51 with Parkinson’s disease, 44 with polymyalgia rheumatica, 25 with neuropathy, 25 with chronic fatigue syndrome, 25 with dementia, 21 with migraine headache, 19 with multiple sclerosis, and 78 with other disorders completed the 24-week study to achieve a composite average symptom improvement of 76% with equal response rates. The participants averaged ingesting 12 mg of hydrocortisone per day. No significant adverse reactions were observed.
Conclusions: Patient self-administration of hydrocortisone safely achieves superior symptom control for 38 hydrocortisone-responding disorders at equal rates and symptom improvements to confirm and amplify an earlier double-blind study finding on rheumatoid arthritis. These results are consistent with the body having an inflammation control system and chronic inflammation being a disorder unto itself with differing symptoms sets dependent on its location.
Clinical Trials Government Identifier: NCT03558971

Keywords: general theory of inflammation, chronic inflammation, inflammation control system, pain, osteoarthritis, fibromyalgia

Corrigendumfor this paper has been published


中文翻译：

---

炎症的一般理论：患者自行给予氢化可的松，通过将剂量与症状强度相匹配，可以安全地实现对氢化可的松反应性疾病的良好控制。

目的：确定患者自行施用氢化可的松是否能够安全地实现对所有氢化可的松反应性疾病的良好症状控制，就像对艾迪生氏病和类风湿性关节炎一样。
方法：在一项为期 24 周的开放研究中，2428 名患有氢化可的松反应性疾病的参与者通过每天服用氢化可的松片剂将症状降至最低状态。此后，参与者使用为期 5 天的低剂量氢化可的松疗法来抑制随后的疾病恶化（发作），以维持最低的症状状态。最大限度地减少情绪创伤、感染、过敏和伤害等压力源，以减少疾病强度、氢化可的松消耗和参与者的不适。
结果： 2015 名参与者，601 名患有纤维肌痛，579 名患有骨关节炎，246 名患有类风湿性关节炎，226 名患有未分化关节炎，75 名患有背痛，51 名患有帕金森病，44 名患有风湿性多肌痛，25 名患有神经病，25 名患有慢性疲劳综合症， 25 名痴呆症患者、21 名偏头痛患者、19 名多发性硬化症患者和 78 名其他疾病患者完成了为期 24 周的研究，在相同的缓解率下，复合平均症状改善了 76%。参与者平均每天摄入 12 毫克氢化可的松。未观察到明显的不良反应。
结论：患者自行服用氢化可的松可以以相同的速度安全地实现对 38 种氢化可的松反应性疾病的优异症状控制，并改善症状，以证实和扩大早期关于类风湿性关节炎的双盲研究结果。这些结果与具有炎症控制系统的身体一致，慢性炎症本身就是一种疾病，其症状取决于其位置。
临床试验政府标识符： NCT03558971

关键词：炎症一般理论、慢性炎症、炎症控制系统、疼痛、骨关节炎、纤维肌痛

本文勘误表已发表